TY - JOUR T1 - Smoking modulates different secretory subpopulations expressing SARS-CoV-2 entry genes in the nasal and bronchial airways JF - medRxiv DO - 10.1101/2021.03.30.21254564 SP - 2021.03.30.21254564 AU - Ke Xu AU - Xingyi Shi AU - Chris Husted AU - Rui Hong AU - Yichen Wang AU - Boting Ning AU - Travis Sullivan AU - Kimberly M Rieger-Christ AU - Fenghai Duan AU - Helga Marques AU - Adam C. Gower AU - Xiaohui Xiao AU - Hanqiao Liu AU - Gang Liu AU - Grant Duclos AU - Avrum Spira AU - Sarah A. Mazzilli AU - Ehab Billatos AU - Marc E. Lenburg AU - Joshua D. Campbell AU - Jennifer Beane Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254564.abstract N2 - Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 SARS-CoV-2), which infects host cells with help from the Viral Entry (VE) proteins ACE2, TMPRSS2, and CTSL1–4. Proposed risk factors for viral infection, as well as the rate of disease progression, include age5,6, sex7, chronic obstructive pulmonary disease7,8, cancer9, and cigarette smoking10–13. To investigate whether the proposed risk factors increase viral infection by modulation of the VE genes, we examined gene expression profiles of 796 nasal and 1,673 bronchial samples across four lung cancer screening cohorts containing individuals without COVID-19. Smoking was the only clinical factor reproducibly associated with the expression of any VE gene across cohorts. ACE2 expression was significantly up-regulated with smoking in the bronchus but significantly down-regulated with smoking in the nose. Furthermore, expression of individual VE genes were not correlated between paired nasal and bronchial samples from the same patients. Single-cell RNA-seq of nasal brushings revealed that an ACE2 gene module was detected in a variety of nasal secretory cells with the highest expression in the C15orf48+ secretory cells, while a TMPRSS2 gene module was most highly expressed in nasal keratinizing epithelial cells. In contrast, single-cell RNA-seq of bronchial brushings revealed that ACE2 andTMPRSS2 gene modules were most enriched in MUC5AC+ bronchial goblet cells. The CTSL gene module was highly expressed in immune populations of both nasal and bronchial brushings. Deconvolution of bulk RNA-seq showed that the proportion of MUC5AC+ goblet cells was increased in current smokers in both the nose and bronchus but proportions of nasal keratinizing epithelial cells, C15orf48+ secretory cells, and immune cells were not associated with smoking status. The complex association between VE gene expression and smoking in the nasal and bronchial epithelium revealed by our results may partially explain conflicting reports on the association between smoking and SARS-CoV-2 infection.Competing Interest StatementA. S. is an employee of Johnson and Johnson Services, Inc, and has received personal fees from Veracyte Inc outside the submitted work. M. E. L. reports grants and personal fees from Johnson and Johnson and is a shareholder in Metera Pharmaceuticals; he also has a patent US PTO 9,677,138 issued. G. D. is now an employee of AstraZeneca.Funding StatementThe DECAMP study is supported by funds from the Department of Defense (W81XWH-11-2-0161), the National Cancer Institute (U01CA196408), and Johnson and Johnson Services, Inc (JJSI). The SU2C study is supported by a Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Cancer Research Grant (grant number: SU2C-AACR-DT23-17 to S.M. Dubinett and A.E. Spira). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. The IDA study is supported by a Department of Defense Idea Development Award W81XWH-14-1-0234 (J. B.). Part of the work on method development was funded by the National Library of Medicine (NLM) RO1LM013154-01 (JDC). This work was also funded in part by the National Cancer Institute (NCI) Human Tumor Atlas Network (HTAN) COVID NOSI 3U2CCA233238-01S1 (A. S., J. B., J. C., S. M.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research has been approved by Boston Medical Center under IRB number H-31755 and H-32479.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are either available online or currently being processed to be published on Gene Expression Omnibus (GEO). https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80796 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi ER -